Heron Therapeuti (HRTX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Heron Therapeuti stock (HRTX) is currently trading at $0.76. Heron Therapeuti PS ratio (Price-to-Sales) is 0.95. Analyst consensus price target for HRTX is $4.33. WallStSmart rates HRTX as Sell.
- HRTX PE ratio analysis and historical PE chart
- HRTX PS ratio (Price-to-Sales) history and trend
- HRTX intrinsic value — DCF, Graham Number, EPV models
- HRTX stock price prediction 2025 2026 2027 2028 2029 2030
- HRTX fair value vs current price
- HRTX insider transactions and insider buying
- Is HRTX undervalued or overvalued?
- Heron Therapeuti financial analysis — revenue, earnings, cash flow
- HRTX Piotroski F-Score and Altman Z-Score
- HRTX analyst price target and Smart Rating
Heron Therapeuti
📊 No data available
Try selecting a different time range
Smart Analysis
Heron Therapeuti (HRTX) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, institutional own.. Concerns around market cap and peg ratio. Significant fundamental concerns warrant caution or avoidance.
Heron Therapeuti (HRTX) Key Strengths (2)
Paying less than $1 for every $1 of annual revenue
83.70% of shares held by major funds and institutions
Supporting Valuation Data
Heron Therapeuti (HRTX) Areas to Watch (7)
PEG ratio is negative or unavailable
Company is destroying shareholder value
Revenue declining -0.50%, a shrinking business
Company is losing money with a negative profit margin
Near-zero operating margins, business under pressure
Very expensive at 11.1x book value
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Heron Therapeuti (HRTX) Detailed Analysis Report
Overall Assessment
This company scores 26/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 2 register as strengths (avg 10.0/10) while 7 fall into concern territory (avg 0.9/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Institutional Own.. Valuation metrics including Price/Sales (0.95) suggest the stock is attractively priced.
The Bear Case
The primary concerns are PEG Ratio, Return on Equity, Revenue Growth. Some valuation metrics including PEG Ratio (N/A), Price/Book (11.05) suggest expensive pricing. Growth concerns include Revenue Growth at -0.50%, which may limit upside. Profitability pressure is visible in Return on Equity at -2409.00%, Operating Margin at 0.09%, Profit Margin at -13.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -2409.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -0.50% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. PEG Ratio and Return on Equity are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
HRTX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
HRTX's Price-to-Sales ratio of 0.95x trades 19% below its historical average of 1.17x (0th percentile). The current valuation is 33% below its historical high of 1.41x set in Feb 2026, and 0% above its historical low of 0.95x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~1.4x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Heron Therapeuti (HRTX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Heron Therapeuti is in a turnaround phase, with management focused on restoring profitability. Revenue reached 155M with 50% decline year-over-year. The company is currently unprofitable, posting a -13.0% profit margin.
Key Findings
Revenue contracted 50% YoY. Worth determining whether this is cyclical or structural.
The company is unprofitable with a -13.0% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Heron Therapeuti.
Bottom Line
Heron Therapeuti is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(26 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 8:25:12 AM
About Heron Therapeuti(HRTX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Heron Therapeutics, Inc., a biotechnology company, is dedicated to developing treatments to address unmet medical needs. The company is headquartered in San Diego, California.